CVOTs for diabetes drugs are here to stay.
Category: NYSE:GSK
Big Data Is Remaking Big Pharma
Big Pharma is in a rut. The industry keeps spending more and yet making fewer scientific breakthroughs.
But help is on the way.
23andMe Gets $300 Million Boost From GlaxoSmithKline To Develop New Drugs
GlaxoSmithKline, a London-based drug giant is partnering with 23andMe, the San Francisco genetics startup, to develop new medicines. The companies will split costs and profits equally, and Glaxo will make a $300 million investment in 23andMe. The colla…
